Attorney Docket No. PC110  The the certify that this correspondence is being deposited with the United States Postal Service and first-class mail in an envelope addressed to the Transfer Stop Amendment, Commissioner for Patents To. Box 1450, Alexandria VA 2231 F1436 form is 24th of June 2005.  By  (Signature of person mailing)  Erica L. Smith  (Typed or printed name of person)		<b>℃</b> \		PATEN'
The Court of that this correspondence is being deposited with the United States Postal Service against class mail in an envelope addressed to the Trape of States Amendment, Commissioner for Patents (O. Dox 1450, Alexandia VA 2234 7 1437 1447 in a 24th of June 2005.  By  (Signature of person mailing)  Erica L. Smith	JUN 2 7	2005 5		Attorney Docket No. PC11076
(Signature of person mailing)  Erica L. Smith	* '	I heteby	certify that this correspondence is being deposited with the Duited States Postal Service	ce an first-class mail in an envelope addressed to:
(Signature of person mailing)  Erica L. Smith	AT & TRA		p Amendment, Commissioner for Patents 40, Box 1450, Alexandria VA 2231 4 14	57 17 his 24th of June 2005.
	•	,	(Signature of person mailing)	7
(Typed or printed name of person)	5		Erica L. Smith	
	•		(Typed or printed name of person)	

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In-the application of:	)
Laura C. Blumberg, et al.	)
Serial No.: 09/972,177	) Group Art Unit: 1624
Filed: October 5, 2001	) Examiner: Brenda Libby Coleman
Title: BRIDGED PIPERAZINE DERIVATIVES	) ) )

Mail Stop Amendment Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Sir:

Applicants hereby submit to the U.S. Patent and Trademark Office form PTO-FB-A820 and a copy of the documents cited therein to ensure compliance with the continuing duty of candor as set forth in 37 C.F.R. § 1.56. This submission is intended to augment, and not replace, the Information Disclosure Statement filed previously on August 26, 2002.

In the judgment of the undersigned, portions of the documents cited in form PTO-FB-A820 may be material to the present application, however, the filing of this Information Disclosure Statement shall not be construed to be an admission that the documents cited are, or are considered to be, material with regard to patentability as defined in 37 C.F.R. § 1.56(b). The documents have not been reviewed in sufficient detail to make any other

PATENT Attorney Docket No. PC11076A

representation and, in particular, no representation is intended as to the relative importance of any portion of the documents. This statement is not a representation that the listed documents have an effective date early enough to be "prior art" within the meaning of 35 U.S.C. § 102 or § 103.

As this Information Disclosure Statement is being filed before the mailing of a first Office Action after the filing of a request for continued examination, Applicants believe that no fee is due pursuant to 37 C.F.R. § 1.97(b)(4). However, to the extent a fee is necessary, please apply any charges or credits to Deposit Account No. 16-1445.

Respectfully submitted,

Date: June 24,2005

Christopher J. Verni Attorney for Applicants

Reg. No. 48,322

Customer No. 28523

Pfizer Inc.
Patent Department, MS 8260-1611
Eastern Point Road
Groton, Connecticut 06340
(860) 686-2032

Doc. #: 83165v1

JUN 2 7 2005 5

MATION DISCLOSURE CITATION ATTY. DOCKET NO. PC11076A SERIAL NO. 09/972,177 (Use several sheets if necessary) **APPLICANT** Laura C. Blumberg, et al. FILING DATE October 5, 2001 **GROUP** 1624 **U.S. PATENT DOCUMENTS** EXAMINER !NITIAL DOCUMENT NUMBER NAME CLASS FILING DATE SUBCLASS US 3 9 4 2 1/28/94 Heimlich, et al. 167 82 US 3 4 9 3 9 1/27/70 Peters, et al. 424 20 US 3 5 3 8 1 11/3/70 Polli, et al. 424 19 US 0 6 0 8 11/29/77 Groppenbacher 424 33 US 3 6 11/6/79 Dempski, et al. 424 19 FOREIGN PATENT DOCUMENTS DOCUMENT NUMBER DATE COUNTRY CLASS SUBCLASS TRANSLATION YES NO wo 0 2 8 3/14/01 International C07D 295/185 OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) Combadiere, C., et al., <u>J. Biol. Chem.</u>, "Monocyte Chemoattractant Protein-3 Is a Functional Ligand for CC Chemokine Receptors 1 and 2B", Vol. 270, No. 50, pages 29671-29675 (1995) Cook, et al., Science, "Requirement of MIP-1-alpha for an Inflammatory Response to Viral Infection", Vol. 269, page 1583 (1995) Kuna, et al., J. Allergy Clin. Immunol., "Allergens, IgE, Mediators, Inflammatory Mechanisms", Vol. 97, No. 1 page. 321 (1996) Smith, et al., J. Immunol., "Production and Function of Murine Macrohage Inflammatory Protein-1 x in Bleomycin-Induced Lung Injury", Vol. 153, page 4704 (1994) Teran, L., et al., J. Immunol., "Eosinophil Recruitment Following Allergen Challenge is Associated with the Release of the Chemokine RANTES into Asthmatic Airways", Vol. 157, pages 1806-1812 (1996) Current Protocols in Immunology, Chapter 6. Cytokines and Their Cellular Receptors: Unit 6.12-Biological Responses to Chemokine Superfamily Members: "Basic Protocol 1: Measurement of Granulocyte Chemotaxis by Chemokines Using Microche" (John Wiley Current Protocols in Immunology, Chapter 6: Cytokines and Their Cellular Receptors: Unit 6.12-Biological Responses to Chemokine Superfamily Members: "Basic Protocol 2: Measurement of Monocyte Chemotaxis by Chemokines Using Microchemotaxis Assays", (John Wiley and Sons, NY) 1991 Current Protocols in Immunology, Chapter 6. Cytokines and Their Cellular Receptors: Unit 6.12-Biological Responses to Chemokine Superfamily Members: "Basic Protocol 3: Measurement of Lymphocyte Chemotaxis By Chemokines Using Microchemotaxis Assays" U.S. Provisional No. 60/193,789 filed March 31, 2000 as PC10770 **EXAMINER** DATE CONSIDERED

Conforms with FORM PTO-FB-A820

INFORMATION DISCLOSURE